Copyright
©2014 Baishideng Publishing Group Inc.
World J Gastroenterol. Aug 21, 2014; 20(31): 11012-11018
Published online Aug 21, 2014. doi: 10.3748/wjg.v20.i31.11012
Published online Aug 21, 2014. doi: 10.3748/wjg.v20.i31.11012
Table 1 Assessment of small bowel lesions
| 0 | Normal |
| 1 | Petechiae |
| 2 | Erosion |
| 3 | Ulcer (< 3) |
| 4 | Ulcer (≥ 3) |
| 5 | Other: denuded mucosa and lymphangiectasis |
Table 2 Characteristics of the subjects undergoing capsule endoscopy
Table 3 Percentage of subjects with mucosal breaks at baseline and post-treatment capsule endoscopy n (%)
Table 4 Number of small bowel mucosal breaks in subjects with at least one break at baseline and post-treatment capsule endoscopy
Table 5 Comparison of injuries observed in the nonsteroidal anti-inflammatory drug control group vs the nonsteroidal anti-inflammatory drug-muscovite group n (%)
| Type of injury | NSAID-muscovite group | NSAID control group | P value1 |
| Petechiae | 3 (19) | 7 (50) | 0.070 |
| Erosion | 4 (25) | 10 (71) | 0.011 |
| Ulcer | 4 (25) | 8 (57) | 0.073 |
| Denuded areas | 1 (6) | 3 (21) | 0.315 |
| Lymphangiectasis | 1 (6) | 8 (57) | 0.004 |
Table 6 Classification of small bowel injury severity after treatment n (%)
Table 7 Number of small bowel mucosal breaks per tertile along the length of the small bowel
- Citation: Huang C, Lu B, Fan YH, Zhang L, Jiang N, Zhang S, Meng LN. Muscovite is protective against non-steroidal anti-inflammatory drug-induced small bowel injury. World J Gastroenterol 2014; 20(31): 11012-11018
- URL: https://www.wjgnet.com/1007-9327/full/v20/i31/11012.htm
- DOI: https://dx.doi.org/10.3748/wjg.v20.i31.11012
